Regulating cell-based regenerative medicine: the challenges ahead

Regenerative Medicine
Robin R AliMartin R Wilkins

Abstract

Those working in the regenerative medicine field currently face numerous regulatory and related challenges. This Perspective captures some of the key ideas of a UK-based working group drawn from academic, clinical and industrial communities and also identifies some key steps that should be taken in the UK and elsewhere to address these challenges.

Citations

Nov 14, 2015·Regenerative Medicine·Tania BubelaSowmya Viswanathan
Mar 12, 2016·Bioscience, Biotechnology, and Biochemistry·Atsushi UenoyamaKenji Izumi
Mar 29, 2016·Social Science & Medicine·John Gardner, Andrew Webster
Jul 2, 2016·Advances in Wound Care·Geoffrey C Gurtner, Mary Ann Chapman
Nov 3, 2017·Regenerative Medicine·John Gardner

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

European Addiction Research
Richard VellemanUK Alcohol, Drugs and the Family Research Group
Journal of Advanced Nursing
Andrew WattersonColette McIntosh
Complementary Therapies in Medicine
Felicity L BishopG Lewith
© 2021 Meta ULC. All rights reserved